$NRXP

NRx Pharmaceuticals (NRXP) disputes Kadima's claims over a failed acquisition, citing a binding arbitration agreement and unmet closing conditions. NRx argues the acquisition is immaterial to its business. The dispute involves an agreement executed in May 2025. NRx is advancing initiatives like a partnership with Zeta Surgical and the SPARC-TMS trial. The company maintains the dispute is non-material to its financial outlook.

NRx Pharmaceuticals (NRXP) targets 2026 FDA approval for KETAFREE, its preservative-free ketamine product, with one remaining deficiency in review. The company ordered 5M units for launch and estimates a $750M market. NRx also advances a 400-patient DARPA-backed trial for NRX-101 and aims for 2027 approval of NRX-100. Q2 2026 net loss improved to $18M, with $26.7M cash on hand.

NRx Pharmaceuticals (NRXP) reported Q2 2026 results, highlighting FDA progress for preservative-free ketamine, $22.3M raised, and DARPA funding potential. The company submitted the final FDA attestation, is manufacturing 5M doses, and expects approval in 2026. Cash reserves support operations for at least a year.

NRx Pharmaceuticals (Nasdaq: NRXP) reported Q2 2026 results for the quarter ended June 30, 2026 and said its preservative-free ketamine ANDA faces one FDA major deficiency on a vial luer lock attestation, with a 2026 approval target. It reported six-month net loss of $18.0M and cash of $26.7M after a $22M+ offering.

NRX Pharmaceuticals’ Q2 2026 earnings call covered ketamine pipeline progress. Management said the FDA found no major deficiencies for preservative-free ketamine ANDA, targeting 2026 approval, and expects 2027 approval for NRX-100 using real-world evidence guidance. For NRX-101, DARPA-funded SPARC-TMS Phase 2/3 trial is planned with 400 patients. Q2 2026 cash was about $26.7M; net loss was $18M for six months ended June 30, 2026.

NRX Pharmaceuticals (NRXP) reported a net loss of $18.0M for the six months ended June 30, 2026, versus $23.1M a year earlier, and an operating loss of $11.3M. Cash and cash equivalents were about $26.7M. The company said an underwritten public offering raised $22.3M gross proceeds and expects funding for at least one year.

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17 th at 4:30pm ET Key recent and second quarter highlights include: ● Completed first-cycle FDA review of the

NRx Pharmaceuticals (NASDAQ:NRXP) said it submitted an FDA attestation for its preservative-free ketamine ANDA, describing it as a final verification step, though it has not received a new GDUFA action date. The company plans launch inventory of 4-5 million vials and expects shipping within days of approval. It targets hospitals and other settings and also plans branded NRX-100/NRX-101.

NRx Pharmaceuticals (Nasdaq: NRXP) said it will hold an Aug. 10, 2026 conference call to discuss the FDA’s completion of the first-cycle review of its ANDA for preservative-free ketamine and the company’s commercial plans. Executives including CEO Jonathan Javitt will participate. A webcast and replay will be available on the company’s site.

NRx Pharmaceuticals (Nasdaq: NRXP) said the FDA completed the first-cycle review of its ANDA for preservative-free IV ketamine, finding no major deficiencies in the drug product, ingredients, labeling, or CMC. A remaining packaging-related issue concerns luer lock vial certification. FDA will review the requested manufacturer attestation in the shortest possible cycle. No new clinical data are required.